Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase.

Q3 Medicine

Voprosy virusologii Pub Date : 2024-07-05 DOI:10.36233/0507-4088-232

E N Ozhmegova, A I Kuznetsova, A V Lebedev, A A Antonova, K V Kim, Y M Munchak, A S Tumanov, E V Kazennova

{"title":"Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase.","authors":"E N Ozhmegova, A I Kuznetsova, A V Lebedev, A A Antonova, K V Kim, Y M Munchak, A S Tumanov, E V Kazennova","doi":"10.36233/0507-4088-232","DOIUrl":null,"url":null,"abstract":"Introduction: The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF). A62V is a typically polymorphic mutation in HIV-1 sub-subtype A6, which is the most widespread virus variant in Russia.Materials and methods: The European EuResist (EIDB) database was queried to form two equivalent groups of patients: group 1 ‒ patients with A62V at baseline treated with TDF or TAF on the first-line therapy, group 2 ‒ patients without A62V at baseline treated with TDF or TAF on the first-line therapy. Each group included 23 patients.Results: There was no statistical difference between the two groups in virologic efficacy in 4, 12, and 24 weeks after the start of antiretroviral therapy (ART) and in the frequency of virologic failures.Conclusion: This study has some limitations, and the exact role of A62V in the efficacy of the first-line ART based on tenofovir deserves further investigation.","PeriodicalId":23669,"journal":{"name":"Voprosy virusologii","volume":"69 3","pages":"231-240"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy virusologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36233/0507-4088-232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF). A62V is a typically polymorphic mutation in HIV-1 sub-subtype A6, which is the most widespread virus variant in Russia.

Materials and methods: The European EuResist (EIDB) database was queried to form two equivalent groups of patients: group 1 ‒ patients with A62V at baseline treated with TDF or TAF on the first-line therapy, group 2 ‒ patients without A62V at baseline treated with TDF or TAF on the first-line therapy. Each group included 23 patients.

Results: There was no statistical difference between the two groups in virologic efficacy in 4, 12, and 24 weeks after the start of antiretroviral therapy (ART) and in the frequency of virologic failures.

Conclusion: This study has some limitations, and the exact role of A62V in the efficacy of the first-line ART based on tenofovir deserves further investigation.

查看原文本刊更多论文

基于替诺福韦的一线抗逆转录病毒疗法对已有逆转录酶 A62V 突变的 HIV 感染者的疗效。

简介：在接受替诺福韦（TDF）和替诺福韦-阿拉非那胺（TAF）等一线治疗的患者中，逆转录酶中的氨基酸替代物 A62V 被确定为与病毒学失败相关的突变。A62V是HIV-1亚型A6的典型多态变异，而A6亚型是俄罗斯最普遍的病毒变异：通过查询欧洲 EuResist（EIDB）数据库，将患者分为两组：第 1 组--基线值为 A62V 的患者，一线疗法为 TDF 或 TAF；第 2 组--基线值为 A62V 的患者，一线疗法为 TDF 或 TAF。每组包括 23 名患者：结果：两组患者在抗逆转录病毒疗法（ART）开始后4周、12周和24周的病毒学疗效以及病毒学失败的频率方面没有统计学差异：本研究存在一定的局限性，A62V 在基于替诺福韦的一线抗逆转录病毒疗法疗效中的确切作用值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Voprosy virusologii Medicine-Infectious Diseases

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： The journal deals with advances in virology in Russia and abroad. It publishes papers dealing with investigations of viral diseases of man, animals and plants, the results of experimental research on different problems of general and special virology. The journal publishes materials are which promote introduction into practice of the achievements of the virological science in the eradication and incidence reduction of infectious diseases, as well as their diagnosis, treatment and prevention. The reader will find a description of new methods of investigation, new apparatus and devices.